LIB Therapeutics was founded in 2015 by Drs. Evan Stein and August Troendle as a private, self-funded company with assets from BMS. The LIB model is totally virtual, highly flexible, and designed to move through all phases of development and regulation as quickly and smoothly as possible. This has enabled LIB to develop and optimize the manufacturing of its lead asset, lerodalcibep (LIB003), complete all preclinical toxicology...
LIB Therapeutics was founded in 2015 by Drs. Evan Stein and August Troendle as a private, self-funded company with assets from BMS. The LIB model is totally virtual, highly flexible, and designed to move through all phases of development and regulation as quickly and smoothly as possible. This has enabled LIB to develop and optimize the manufacturing of its lead asset, lerodalcibep (LIB003), complete all preclinical toxicology, phase 1, phase 2 dose selection, a 52-week phase 2b trials, and initiate and enroll 7 large global phase 3 trials in under 6 years.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.